Hormone replacement therapy to maintain cognitive function in women with dementia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Hogervorst, Eva ^a   Yaffe, Kristine ^b   Richards, Marcus ^c   Huppert, Felicia A H ^d  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

*Hormone replacement therapy; Cognition disorders prevention control ; Cognition *drug effects; physiology ; Dementia *drug therapy ; Estrogen replacement therapy; Female; Humans; Memory drug effects ; Postmenopause blood ; Randomized controlled trials as topic

Indexed keywords

BEIMEILI; CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; THIAMINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; LANGUAGE ABILITY; LANGUAGE TEST; LOW DRUG DOSE; MENTAL FUNCTION; MENTAL PERFORMANCE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; PATIENT COMPLIANCE; POSTMENOPAUSE; RATING SCALE; RECALL; RECOGNITION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL MEMORY;

EID: 70249121973     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003799.pub2     Document Type: Review

References (51)

1. Asthana S, Craft S, Baker LD, RaskindMA, Birnbaum RS, Lofgreen C, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with AD: results of a placebo-controlled, double-blind pilot study. Psychoneuroendocrinol- ogy 1999;24:657-677. (Pubitemid 29277256)
2. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, RaskindMA, Plymate SR.High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; Vol.57, issue 4:605-612
3. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48:S36-S41. (Pubitemid 27230091)
4. Henderson VW, Paganini-Hill A, Miller BL, et al.Estrogen for Alzheimer's disease in women. Neurology 2000;54(2):295-301.
5. Honjo H, Tanaka T, Urabe M, Okada H, Hayashi M, Hayashi K. Senile dementia-Alzheimer's type and estrogen. Horm. Metab. Res. 1995;27:204-207.
6. Caldwell BM, Watson RI. Evaluation of psychologic effects of sex hormone administration in aged women: results of therapy after 6 months. Journal of Gerontology 1952;7:228-244
7. Mulnard RA, Cotman CW, Kawas C, et al.Estrogen replacement therapy for treatment ofmild tomoderate Alzheimer's disease. JAMA 2000;283:1007-1015
8. Wang PN, Liao SQ, Liu CY, et al.Effects of estrogen on cognition, mood, and cerebral blood flow in AD. Neurology 2000;54:2061-2066. (Pubitemid 30397202)
9. Zhang, YX, Luo, G, Guo ZJ, Cui, RY, Wang, LQ, Zhou CL. Quantitative evaluation of the intervention al effect of estrogen on Alzheimer's disease. Chinese Journal of Clinical Rehabilitation 2006;10(30):37-91. (Pubitemid 44236526)
10. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-345. (Pubitemid 16002256)
11. Fillit H. Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in PostmenopausalWomen. Annals of the New York Academy of Sciences 1994;743:233-239
12. Honjo H, Ogino Y, Naitoh K, et al.In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). Journal of Steroid Biochemistry 1989;34:521-525 (Pubitemid 20061838)
13. Kantor HI,Michael CM, Shore E. Estrogen for older women. American Journal of Obstetrics and Gynecology 1973;4:31-47.
14. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrine Journal 1994;41:361-371 (Pubitemid 24297493)
15. OhkuraT, Isse K,Akazawa K,HamamotoM,YaoiY,HaginoN. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994b;1:125-130
16. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type 7 case reports. Dementia 1995;6:99-107.
17. Rigaud AS, Andre G, Vellas B, Touchon J, Pere MD. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003;60:148-149 (Pubitemid 36070671)
18. Yoon B-K, Kim DH, Kan Y, Kim J-W, Shin M-H, Na DL. Hormone replacement therapy in women with Alzheimer's disease: a randomised prospective study. Fertility and Sterility 2003;79(2):274-280 (Pubitemid 36144049)
19. Al-Azzawi F. Pulsatile nasal administration of estradiol for postmenopausal complaints. In: Hogervorst E, Henderson V, Gibbs B, Brinton-Diaz R editor(s). Hormones, Cognition andDementia. Cambridge: Cambridge University Press, 2008.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1999.
21. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Postmenopausal estrogen and prevention bias. Annals of Internal Medicine 1991;115:455-456
22. Chalmers TC, Celano P, Sacks HS, Smith H, Junior. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309:1358-1361 (Pubitemid 14246558)
23. Christie, et al.Reduced plasma oestrogen stimulated neurophysin and delayed response to oestrogen challenge in AD. Psych Med 1990;20:773-777.
24. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. Journal of Clinical Oncology 2001;19 (8):2357-2363 (Pubitemid 32372327)
25. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al.Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11):S10-15.
26. Gibbs RB. Animal studies that support estrogen effects on cognitive performance and the cholinergic basis of the critical period hypothesis. In: Hogervorst E,Henderson V, Gibbs B, Brinton-Diaz R editor (s). Hormones, Cognition and Dementia. Cambridge: Cambridge University Press, 2008.
27. Henderson VH. The critical window hypothesis: hormone exposure and cognitive outcomes after menopause. In: Hogervorst E, Henderson V, Gibbs B, Brinton-Diaz R editor(s). Hormones, Cognition and Dementia. Cambridge: Cambridge University Press, 2008.
28. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 2000;101(3):485-512. (Pubitemid 30953107)
29. Hogervorst E, Bandelow S. Should surgically menopausal women be treated with estrogens to decrease the risk for dementia?. Neurology, Invited Editorial 2007;69(11):1070-1071 (Pubitemid 47517550)
30. Huppert F, Wilcock G. Ageing, cognition and dementia. Age and Ageing 1997;Dec 26(Suppl 4):20-23
31. Launer LJ, Andersen K, Dewy ME, et al.Rates and risk factors for dementia and Alzheimer's disease. Neurology 1999;1:78-84.
32. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD.Hormone replacement therapy and cognition. JAMA 2001;285(11):1489-1499
33. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003122. pub2] (Pubitemid 351807570)
34. Matthews KA, Kuller LH,Wing RR,Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy: are users healthier than nonusers ?. American Journal of Epidemiology 1996;143(10):971-978 (Pubitemid 26140324)
35. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain implications for cognition and aging. Neurology 1997;48:S14-S18. (Pubitemid 27230087)
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;4:939-944 (Pubitemid 14076461)
37. Nappi RE, Sinforiani E, Mauri M, Bono G, Polatti F, Nappi G. Memory functioning atmenopause: impact of age in ovariectomized women. Gynecologic and Obstetric Investigation 1999;47:29-36. (Pubitemid 29026892)
38. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Hormone replacement therapy and stroke: risk, protection or no effect?. Maturitas 2001;38(3):243-261
39. Rodríguez JL, Qizilbash N, López-Arrieta J. Thiamine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD001498]
40. Schulz KF,Chalmers I,Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412
41. Schumaker, et al.The WHIMS: a trial of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998;19:604-621.
42. Shumaker SA, Legault C, Thal L,Wallace RB, Ockene JK, Hendrix SL, et al. and WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: theWomen's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-2662 (Pubitemid 37430136)
43. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al.Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291(24):2947-2958 (Pubitemid 38802684)
44. Silva I, Mor G, Naftolin F. Estrogen and the aging brain. Maturitas 2001;38(1):100-101
45. Toran-Allerand CD. Estrogen as a treatment for AD: commentary. JAMA 2000;284:307-308
46. WegienkaG,Havstad S, Kelsey JL.Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination. Journal of Women's Health 2006; 15(4):369-378
47. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Journal of the American Medical Association 1998;279:688-695.
48. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrogen levels, cognitive performance and risk of cognitive decline in older community women. Journal of the American Geriatrics Sociaty 1998;46: 816-821 (Pubitemid 28328494)
49. Yaffe K, et al.Cognitive decline in women with relation to non-protein bound estradiol concentrations. Lancet 2000;356:708-712 (Pubitemid 30663239)
50. Yesufu A, Bandelow S, Hogervorst E. Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. Women's Health invited review 2007;3(2):173-195 (Pubitemid 46488180)
51. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003799] * Indicates the major publication for the study